- APP NOTE
Align and Prioritize your Antibody Sequences
Antibody drug discovery teams need to analyze both sequencing data and results from the assay data associated with them. It is then critical to efficiently query all this information in parallel to accelerate screening and improve candidate selection efficiency.
- CUSTOMERS
Customer Success
Enterprises involved in therapeutic antibody R&D are choosing Geneious Biologics to screen and manage their antibody sequence data, transforming data management and significantly speeding up candidate selection.
- EBOOK
NGS is Accelerating Therapeutic Antibody Discovery – What Lies Beyond?
With NGS already in play or on the roadmap for many companies involved in therapeutic antibody R&D, this eBook explains why a cloud-based bioinformatics platform is needed to extract maximum value from NGS data.
- WHITE PAPER
Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery
The ability to handle different date types such as NGS data or Sanger sequencing data, as well as numerical data coming from various functional assays, is key when it comes to analysis of antibody and antibody-like molecules.
- CASE STUDY
Bicycle Therapeutics Prepares for an Accelerated Future
Learn how Bicycle Therapeutics has implemented Geneious Biologics to support its growth from innovative biotech start-up into a full-fledged, integrated pharmaceutical company.
- WHITE PAPER
Why Scalable Cloud Data Platforms are the Future of Biologic Drug Development
Find out how a scalable cloud computing data platform that combines data management with sequence analysis workflows can drive competitive advantage and the availability of more effective and safe antibody drugs.
“Geneious Biologics will help us scale-up our screening efforts. We are incorporating more high-throughput sequencing into our core business, and are screening increasingly large quantities of unique and complex VHH-based multi-specific biologics. We sought a bioinformatics platform that provides powerful, fast and deep sequence analysis and, importantly, allows us to consolidate and manage our sequence data in a secure environment that can be shared with our partners.”
– Bruno Dombrecht, Expert Scientist at VIB Discovery Sciences